Quantcast

Latest Sanofi Stories

2014-06-14 12:21:03

-- Real World Outcome Study of Patients with Type 2 Diabetes Presented at American Diabetes Association 74th Scientific Sessions -- BRIDGEWATER, N.J., June 14, 2014 /PRNewswire/ -- Sanofi US announced today results from a real world outcome study of type 2 diabetes (T2D) patients that show switching from Lantus® (insulin glargine [rDNA origin] injection) to insulin detemir demonstrated higher average blood sugar levels (A1C) and lower A1C reduction over a span of 12 months compared...

2014-06-13 08:24:31

SCRS Welcomes INC Research, inVentiv Health, Novartis and Sanofi ELLICOTT CITY, Md., June 13, 2014 /PRNewswire/ -- Leading sponsor and CRO organizations continue to join the Society for Clinical Research Sites' (SCRS) Global Impact Partner (GIP) program at a rapid pace. Since April 1, INC Research, inVentiv Health, Novartis and Sanofi have joined the SCRS GIP program. From its inception only one year ago, the initiative has quickly grown to 25 leading organizations. Global Impact...

2014-06-13 08:23:37

DALLAS, June 13, 2014 /PRNewswire/ -- MarketReportsChina.com adds "Research on China Cardiovascular Drugs Industry, 2014-2018" market intelligence report of 85 pages to its store. Delivery of this report will take 24 hours post purchase. Research on China Cardiovascular Drugs Industry, 2014-2018 says in the next ten years, there is a potential for the growth in cardiovascular diseases treatment field. It is predicted that the growth rate will be of more than 20% from...

2014-06-12 00:22:01

Both doses of investigational drug sarilumab met all three co-primary endpoints PARIS and TARRYTOWN, N.Y., June 12, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today presented positive results from a phase 3 trial of investigational drug sarilumab in rheumatoid arthritis (RA) patients who were inadequate responders to methotrexate (MTX) therapy. New data presented at the meeting showed that sarilumab increased major clinical...

2014-06-11 08:31:09

SAN FRANCISCO, June 11, 2014 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will host an Investor Breakfast on Friday, June 13, 2014 in New York City. Kindred Bio's executive management team will provide an overview of the Company's strategies and Stephen Sundlof, D.V.M, Ph.D., will offer insights into the animal health business from an FDA perspective. Dr. Sundlof was...

2014-06-10 08:31:46

- Veteran of animal health brings depth of expertise to Merial's R&D organization - LYON, France, June 10, 2014 /PRNewswire/ -- Merial, the animal health division of Sanofi, today announced that Fabian Kausche will be leading the company's global research and development (R&D) efforts, effective June 9, 2014. Dr. Kausche brings to the company a wide range of global experience in pharmaceutical and biological R&D and business leadership positions, at both human and animal...

2014-06-04 08:33:25

MONTREAL, June 4, 2014 /CNW Telbec/ - A Canadian study has identified a new strategy for improving the care of patients living with Type 2 Diabetes (T2D) by empowering them to manage their own insulin therapy. The START study (Self-Titration with Apidra® to Reach Target)(1), the first research of its kind, found that T2D patients adjusting their own insulin doses can control the disease and achieve blood sugar targets just as safely and effectively as patients whose treatment is...

2014-06-04 08:32:55

Dr. Kongsamut specializes in age-related and neuroscience/CNS disorders PLANTATION, Fla., June 4, 2014 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP) announced today the appointment of Sam Kongsamut, Ph.D., as Executive Director, Pharmacology, effective immediately. In this role, Dr. Kongsamut will be responsible for accelerating the Company's product development efforts. Dr. Kongsamut is a neuroscientist with a specialized background in preclinical models used in identifying early...

2014-05-28 08:30:29

Companies anticipate providing over-the-counter (OTC) product to treat erectile dysfunction after expiration of certain patents PARIS and INDIANAPOLIS, May 28, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Eli Lilly and Company (NYSE: LLY) today announced an agreement to pursue regulatory approval of nonprescription Cialis (tadalafil). Cialis is currently available by prescription only worldwide for the treatment of men with erectile dysfunction (ED). Under the terms of the...

2014-05-22 08:28:45

Seven-fold lower incidence of VTEs in patients treated with ISIS-FXIRx compared to enoxaparin CARLSBAD, Calif., May 22, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive top-line data from a Phase 2 comparator-controlled study evaluating the incidence of venous thrombolic events (VTE) in patients treated with ISIS-FXI(Rx) undergoing total knee replacement surgery, or total knee arthroplasty (TKA). ISIS-FXI(Rx) inhibits the production of Factor...


Word of the Day
sough
  • A murmuring sound; a rushing or whistling sound, like that of the wind; a deep sigh.
  • A gentle breeze; a waft; a breath.
  • Any rumor that engages general attention.
  • A cant or whining mode of speaking, especially in preaching or praying; the chant or recitative characteristic of the old Presbyterians in Scotland.
  • To make a rushing, whistling, or sighing sound; emit a hollow murmur; murmur or sigh like the wind.
  • To breathe in or as in sleep.
  • To utter in a whining or monotonous tone.
According to the OED, from the 16th century, this word is 'almost exclusively Scots and northern dialect until adopted in general literary use in the 19th.'
Related